Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Lung Neoplasms 10Adenocarcinoma of Lung 7Neoplasms 6Neoplasm Metastasis 5Melanoma 3Glioblastoma 3Carcinoma 3cMET-dysregulated Advanced Solid Tumors 2Sarcoma 2Neoplasms by Site 2Neoplasms by Histologic Type 2Hematologic Neoplasms 2Gliosarcoma 2Colorectal Neoplasms 2cMET Dysegulation Advanced Solid Tumors 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Noonan Syndrome 6 1Neuroblastoma 1Malignant Non-small Cell Neoplasm of Lung Stage IV 1Lymphoproliferative Disorders 1Liver Neoplasms 1Laryngeal Diseases 1Kidney Neoplasms 1Hepatic Impairment 1Glioma 1EGFR-mutant Non-small Cell Lung Cancer 1

Interventions

Fluorouracil 497Bevacizumab 476Oxaliplatin 449Leucovorin 440Irinotecan 408Cetuximab 317Capecitabine 317pembrolizumab 142Folfox protocol 129Panitumumab 117regorafenib 105Colonoscopy 88Nivolumab 81IFL protocol 81Drug Therapy 77trifluridine tipiracil drug combination 73Radiotherapy 66HMPL-013 65Blood Specimen Collection 52Gemcitabine 49Specimen Handling 46Neoadjuvant Therapy 45Standard of Care 44Magnetic Resonance Spectroscopy 43Biopsy 43Chemotherapy, Adjuvant 41Trifluridine 40atezolizumab 38Surveys and Questionnaires 38Cyclophosphamide 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colorectal Neoplasms × capmatinib × Clear all
NCT02386826 2023-09-21

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

SCRI Development Innovations, LLC

Phase 1 Completed
65 enrolled
CNSGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Glioblastoma, Colorectal Neoplasms, Gliosarcoma

NCT02205398 2019-01-22

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Novartis

Phase 1 Terminated
13 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡